Table 2 lncRNAs associated with osteosarcoma chemotherapy resistance

LncRNA TTN-AS1

Via the miR-134-5p and MBTD1, controls drug resistance and apoptosis in OS cells

[49]

LncRNA KCNQ1OT1

In OS, inhibiting resistance by controlling LARP1 mediated by miR-129-5p by knocking down KCNQ1OT1

[50]

OS cells become more sensitive to CDDP if KCNQ1OT1 is knocked out by increasing Kcnq1 expression through DNMT1

[51]

LncRNA MIR17HG

OS resistance to cisplatin is aided by the SP1, MIR17HG, and miR-130a-3p

[46]

LncRNA FENDRR

Reduces the levels of ABCB1 and ABCC1 in OS cells, making them more sensitive to doxorubicin

[52]

LncRNA HOTAIR

Bolsters OS cells' cisplatin resistance via the STAT3 Axis of miR-106a-5p

[47]

LncRNA SNHG16

Sponges miR-16 to increase ATG4B expression, which in turn increases cisplatin resistance

[48]

LncRNA NORAD

Regulates OS's sensitivity to drug resistance by targeting miR-410-3p

[53]

LncRNA ANRIL

Through targeted regulation of miR-125a-5p, OS cell sensitivity to cisplatin can be increased by inhibiting the expression of the lncRNA ANRIL

[54]

LncRNA-SARCC

Targets Hexokinase 2 to increase OS's sensitivity to cisplatin by inhibiting glycolysis through miR-143

[55]

LncRNA MSC-AS1

By binding to microRNA-142, downregulated lncRNA MSC-AS1 increases cisplatin sensitivity

[56]

LncRNA OIP5-AS1

Sponging the miR-340-5p induces the LPAAT, PI3K, AKT, and mTOR signaling pathway, resulting in OS cisplatin resistance

[57]

Through the miR-377-3p/FOSL2 axis, knockdown enhances cisplatin sensitivity in OS

[58]

LncRNA ROR

Sponges miR-153-3p to induce cisplatin resistance in OS

[59]

LncRNA NCK-AS1

In OS cells, inhibiting the lncRNA NCK-AS1 modifies miR-137 to control cisplatin resistance

[60]

LncRNA DNAJC3-AS1

Decreases OS's sensitivity to cisplatin, which was reversed by down-regulating DNAJC3, its sense-cognate gene

[61]

LncRNA HOTTIP

By activating the Wnt/-catenin pathway, lncRNA HOTTIP overexpression increases osteosarcoma cell chemoresistance

[62]